Succinimide-Based Conjugates Improve IsoDGR Cyclopeptide Affinity to α_vβ₃ without Promoting Integrin Allosteric...

Area of Science:

• Biochemistry
• Molecular Biology
• Drug Delivery

Background:

• The isoDGR sequence is a known integrin-binding motif used for tumor targeting.
• Cyclopeptide 2, derived from c(CGisoDGRG), has shown potential as a tumor-homing ligand for nanodrug delivery.

Purpose of the Study:

• To investigate the role of the succinimide ring in cyclopeptide 2's interaction with integrin α_vβ₃.
• To evaluate other isoDGR-containing cyclopeptides as integrin antagonists for tumor targeting.

Main Methods:

• Nuclear Magnetic Resonance (NMR) spectroscopy
• Computational modeling
• Biochemical assays

Main Results:

• The succinimide ring in cyclopeptide 2 stabilizes binding to α_vβ₃, an integrin overexpressed in tumor vasculature.
• Various isoDGR cyclopeptides function as pure integrin antagonists, without allosteric activation.
• These findings support the development of improved α_vβ₃-targeting ligands.

Conclusions:

• The succinimide ring is crucial for enhancing the binding affinity of isoDGR-based ligands to α_vβ₃.
• Designing isoDGR ligands as pure antagonists can avoid unwanted integrin activation.
• These insights facilitate the rational design of novel, effective tumor-targeting molecules.